These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12618880)

  • 21. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma.
    Jayasurya R; Francis G; Kannan S; Lekshminarayanan K; Nalinakumari KR; Abraham T; Abraham EK; Nair MK
    Int J Cancer; 2004 May; 109(5):710-6. PubMed ID: 14999779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
    Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
    Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer.
    Koukourakis MI; Manavis J; Simopoulos C; Liberis V; Giatromanolaki A; Sivridis E
    Am J Clin Oncol; 2005 Oct; 28(5):495-500. PubMed ID: 16199990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
    Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
    J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
    Ringberg A; Anagnostaki L; Anderson H; Idvall I; Fernö M;
    Eur J Cancer; 2001 Aug; 37(12):1514-22. PubMed ID: 11506959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.
    Silvestrini R; Veneroni S; Daidone MG; Benini E; Boracchi P; Mezzetti M; Di Fronzo G; Rilke F; Veronesi U
    J Natl Cancer Inst; 1994 Apr; 86(7):499-504. PubMed ID: 8133533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.
    Choi DH; Kim S; Rimm DL; Carter D; Haffty BG
    Cancer J; 2005; 11(5):404-11. PubMed ID: 16259871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenesis relates to estrogen receptor negativity, c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast.
    Koukourakis MI; Manolas C; Minopoulos G; Giatromanolaki A; Sivridis E
    Int J Surg Pathol; 2003 Jan; 11(1):29-34. PubMed ID: 12598915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
    Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients.
    Castiglione F; Sarotto I; Fontana V; Destefanis M; Venturino A; Ferro S; Cardaropoli S; Orengo MA; Porcile G
    Anticancer Res; 1999; 19(5C):4555-63. PubMed ID: 10650810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
    Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
    Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer.
    Schwandner O; Schiedeck TH; Bruch HP; Duchrow M; Windhoevel U; Broll R
    Eur J Cancer; 2000 Feb; 36(3):348-56. PubMed ID: 10708936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases.
    Sirvent JJ; Salvadó MT; Santafé M; Martínez S; Brunet J; Alvaro T; Palacios J
    Histol Histopathol; 1995 Jul; 10(3):531-9. PubMed ID: 7579801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Value of cancer-related oncoprotein expression as prognostic factors in breast-cancer with one to three axillary lymph nodes positive].
    Zhang G; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
    Gan To Kagaku Ryoho; 1996 Mar; 23 Suppl 1():66-74. PubMed ID: 8702314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.
    Linderholm B; Andersson J; Lindh B; Beckman L; Erlanson M; Edin K; Tavelin B; Grankvist K; Henriksson R
    Eur J Cancer; 2004 Jan; 40(1):33-42. PubMed ID: 14687787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An analysis of relapsed breast cancer in patients previously treated with breast conserving surgery.
    Kim R; Nishimoto N; Osaki A; Kojima J; Fujii S; Inai K; Toge T
    Breast Cancer; 2001; 8(2):146-52. PubMed ID: 11342988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma.
    Giatromanolaki A; Stathopoulos GP; Tsiompanou E; Papadimitriou C; Georgoulias V; Gatter KC; Harris AL; Koukourakis MI
    Cancer; 1999 Oct; 86(8):1421-30. PubMed ID: 10526268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.